Treatment

VG801 clinical trials

1 indexed studies · 0 currently recruiting

AuthorisedPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Open-label, Multi-centre, Dose-exploration Trial to Evaluate the Safety and Preliminary Efficacy of VG801 via Subretinal Injection in Treatment of Patients with Biallelic ABCA4 Mutation-Associated Retinal Dystrophy.
This study is testing a new treatment called VG801 for an inherited eye condition that causes vision loss. Researchers want to see if VG801 is safe and if it helps improve eyesight. It's for adults, and it's one of the first times this treatment is being given to people.
For: Biallelic ABCA4 Mutation-Associated Retinal Dystrophy.
Germany